News

Filter

Current filters:

Repligen

Repligen appoints Tony Hunt as chief executive officer

Repligen appoints Tony Hunt as chief executive officer

21-01-2015

Biologics specialist Repligen has appointed Tony Hunt as the company’s next chief executive officer.

BiosimilarsBoardroomLife TechnologiesRepligenTony Hunt

BioMarin buys rights to Repligen preclinical compounds

23-01-2014

BioMarin Pharmaceuticals has entered into an agreement to purchase from fellow USA-based Repligen Corp…

BioMarin PharmaceuticalBiotechnologyLicensingRare diseasesRepligen

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

Repligen in $70 million deal with Pfizer for SMA program

04-01-2013

USA-based Repligen (Nasdaq: RGEN) saw its share jump 5.6% to $6.63, after the company revealed it has…

BiotechnologyLicensingNeurologicalPfizerPharmaceuticalRare diseasesRepligenRG3039

Repligen plunges as bipolar drug flops in Ph IIb trial

08-03-2011

USA-based Repligen (Nasdaq: RGEN) saw its shares plummet 29.1% to $3.48 by mid-afternoon trading yesterday,…

NeurologicalPharmaceuticalRepligenResearch

Back to top